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Spread, Circulation, and Evolution of the Middle East Respiratory
Syndrome Coronavirus
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Abdullah A. Al Rabeeah,b Rafat F. Alhakeem,b Abdullah Assiri,b Jaffar A. Al-Tawﬁq,f Ali Albarrak,g Mazin Barry,h Atef Shibl,h
Fahad A. Alrabiah,i Sami Hajjar,i Hanan H. Balkhy,j Hesham Flemban,k Andrew Rambaut,l,m Paul Kellam,a,c,d Ziad A. Memishb,n
Wellcome Trust Sanger Institute, Hinxton, United Kingdoma; Global Centre for Mass Gatherings Medicine (GCMGM), Ministry of Health, Riyadh, Kingdom of Saudi Arabiab;
Department of Medical Microbiology, University College London Hospitals NHS Foundation Trust, London, United Kingdomc; Division of Infection and Immunity,
University College London, London, United Kingdomd; Jeddah Regional Laboratory, Ministry of Health, Jeddah, Kingdom of Saudi Arabiae; Saudi Aramco Medical Services
Organization, Saudi Aramco, Dhahran, Kingdom of Saudi Arabiaf; Prince Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabiag; King Saud University, Riyadh,
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Fogarty International Center, NIH, Bethesda, Maryland, USAm; College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabian
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ABSTRACT TheMiddle East respiratory syndrome coronavirus (MERS-CoV) was first documented in the Kingdom of Saudi Ara-
bia (KSA) in 2012 and, to date, has been identified in 180 cases with 43%mortality. In this study, we have determined theMERS-
CoV evolutionary rate, documented genetic variants of the virus and their distribution throughout the Arabian peninsula, and
identified the genome positions under positive selection, important features for monitoring adaptation of MERS-CoV to human
transmission and for identifying the source of infections. Respiratory samples from confirmed KSAMERS cases fromMay to
September 2013 were subjected to whole-genome deep sequencing, and 32 complete or partial sequences (20 were>99% com-
plete, 7 were 50 to 94% complete, and 5 were 27 to 50% complete) were obtained, bringing the total available MERS-CoV
genomic sequences to 65. An evolutionary rate of 1.12 103 substitutions per site per year (95% credible interval [95% CI],
8.76 104; 1.37 103) was estimated, bringing the time to most recent common ancestor to March 2012 (95% CI, December
2011; June 2012). Only oneMERS-CoV codon, spike 1020, located in a domain required for cell entry, is under strong positive
selection. Four KSAMERS-CoV phylogenetic clades were found, with 3 clades apparently no longer contributing to current
cases. The size of the population infected withMERS-CoV showed a gradual increase to June 2013, followed by a decline, possi-
bly due to increased surveillance and infection control measures combined with a basic reproduction number (R0) for the virus
that is less than 1.
IMPORTANCE MERS-CoV adaptation toward higher rates of sustained human-to-human transmission appears not to have oc-
curred yet. While MERS-CoV transmission currently appears weak, careful monitoring of changes inMERS-CoV genomes and
of the MERS epidemic should be maintained. The observation of phylogenetically relatedMERS-CoV in geographically diverse
locations must be taken into account in efforts to identify the animal source and transmission of the virus.
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The Middle East Respiratory Syndrome Coronavirus (MERS-CoV)was first detected in the Kingdomof Saudi Arabia (KSA)
in 2012 (1–4), and to date, infection with the virus has been iden-
tified in 180 patients with 43%mortality (5). Previously, the SARS
coronavirus emerged from an animal reservoir (6), and a zoonotic
event may also provide the source of MERS-CoV; however, no
consistent pattern of animal exposure has been observed with
MERS cases. Serological studies have identified a high prevalence
of MERS-CoV reactive antibodies in camels in Oman, the Canary
Islands, and Egypt (7, 8), and fragments of MERS-CoV sequence
have been reported from bats (9) and camels (10). However, to
date, MERS-CoV itself has not been isolated from any nonhuman
source. If such an animal reservoir exists, MERS-CoV epidemiol-
ogy could be explained by intermittent animal-to-human trans-
mission seeding clusters of human-to-human transmission, but
with a reproduction number (R0) of less than 1 (11, 12), these
clusters eventually disappear. An alternative hypothesis is that the
virus has now infected a sufficient number of humans to account
for the observed distribution and diversity of the virus but the
infection is asymptomatic in many individuals. A recent serosur-
vey of 363 individuals in the Saudi Arabia failed, however, to find
MERS-CoV-seropositive individuals (13).
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A detailed description of MERS-CoV evolution is useful to
assess public health risks, to help identify the source of new infec-
tions, and to detect viral adaptation to human transmission. In
this report, we advance our knowledge of the MERS-CoV out-
break with complete or partialMERS-CoV genome sequences ob-
tained directly from 32 recent MERS patient samples from cases
between July and September 2013, bringing the total available
MERS-CoV genomic sequences to 65 (37%of the 178MERS cases
reported globally).
RESULTS
Phylogenetic analysis. All PCR-confirmed MERS case samples
from Saudi Arabia were processed for whole-genome deep se-
quencing (14, 15), adding 32 new MERS-CoV genome sequences
to the publically available data set. The phylogenetic relationship
of all MERS-CoV genomes was inferred from the 33 previously
published genomes (2, 10, 14–16) and 32 new sequences (Fig. 1).
The previously described Al-Hasa clade (17) has expanded, with 6
new members. The Riyadh_3 clade, which includes virus from a
Qatari patient diagnosed in London (15) and aUnited Arab Emir-
ates patient diagnosed in Munich (16) (Fig. 1), has increased to 9
members since the previous report (17) and includes new viruses
from Riyadh, Wadi-Ad-Dawasir, and Ta’if. The Buraidah_1 vari-
ant (Fig. 1), first observed with Buraidah_1_2013, has now ex-
panded to include a virus from Ta’if, two viruses from Khamis
Mushait in the southern province of Asir, and the UAE_Dubai
FIG 1 Bayesian-inferred phylogeny of the 32 new MERS-CoV sequences combined with the 33 previously available genomes (EMC/2012 [JX869059],
Jordan_N3 [KC776174], Munich_AbuDhabi_2013 [KF192507], England-Qatar_2012 [KC667074], Al-Hasa_1_2013 [KF186567], Al-Hasa_2_2013
[KF186566], Al-Hasa_3_2013 [KF186565], Al-Hasa_4_2013 [KF186564, plus all previously published MERS-CoV sequences 17], England2-HPA [http://
www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/MERSCoV/respPartialgeneticsequenceofnovelcoronavirus/], France_UAE_2013 [KF745068],
Qatar_3_2013 [KF961221], and Qatar_4_2013 [KF961222]). All new genome sequences from this study are labeled in red. Clades are marked with vertical bars
on the right and (with the exception of clade A and the Al-Hasa clade) named by the initial genome in the clade. The scale bar indicates the genetic distance, in
substitutions per site, from the arbitrary midpoint root. Bayesian posterior probabilities for each clade are listed above the relevant node.
Cotten et al.
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_France_patient_1 virus identified in a United Arab Emirates
(UAE) patient in Valenciennes, France.
Most of the new genomes cluster with the previous singleton
Hafr-Al-Batin_1_2013 genome, which appeared in the northeast
of Saudi Arabia on 4 June 2013 (Fig. 1). The later Hafr-Al-Batin
cases include a family cluster of MERS cases. Sequences were ob-
tained from three contacts of the index case (Hafr-Al-Batin_4,
Hafr-Al-Batin_5, and Hafr-Al-Batin_6) and a contact of Hafr-Al-
Batin_6 (Hafr-Al-Batin_2). The four contact sequences cluster
together. The close similarity between the Hafr-Al-Batin clade vi-
ruses and Riyadh_12_2013 (Fig. 1) indicates a possible link be-
tween these cases that has not been revealed epidemiologically.
Viruses from recent Madinah cases (Madinah_1_2013 and
Madinah_3_2013) and three Riyadh viruses (Riyadh_13-2013,
Riyadh_14_2013, and Riyadh_15_2013) cluster closely. In addi-
tion, two virus genomes from Qatar MERS patients in October
2013 (10) also cluster in the Hafr-Al-Batin_1 clade. No additional
genomes were found in clade A or in the Bisha_1/Riyadh_1 clade.
A time-resolved phylogeny was generated from all epidemio-
logically unlinked viruses with genome coverage of 30%. The
geographical locations of the ancestral viruses were coestimated
andmarked by color coding in the phylogenetic tree (Fig. 2), lead-
ing to a prediction that the ancestors of most of the viral clades
originated in Riyadh.
Evolutionary rate. A critical feature of an emerging virus is
how quickly it is changing. The evolutionary rate for the updated
set of 42 epidemiologically unlinked MERS-CoV genomes was
estimated as 1.12  103 substitutions per site per year (95%
credible interval [95% CI], 8.76  104; 1.37  103), bringing
the time to most recent common ancestor (tMRCA) for clade B
FIG 2 Time-resolved phylogenetic tree of all concatenated coding regions of the 42 phylogenetically distinct MERS-CoV genomes (see Materials andMethods
for further details). A discrete traits model implemented in BEAST version 1.7.5 (36) was used to determine the most probable geographical location for each
branch; a change in branch color indicates a geographical location change during its evolutionary history. Posterior probabilities for the inferred geographical
locations are indicated at the nodes, an asterisk at a node indicates a posterior probability of0.9 for that clade, and time is indicated on the x axis.
Spread, Circulation, and Evolution of MERS-CoV
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(all MERS-CoV except clade A) to March 2012 (95% CI, Decem-
ber 2011; June 2012). This is within the credible interval bounds of
the previous estimation (17). Two codon positions in the MERS-
CoV genome exhibit evidence of episodic selection using mixed
effects model of evolution (MEME; see Materials and Methods),
spike codon 1020 (P 0.014) and, more weakly, spike codon 158
(P 0.059). Furthermore, under an alternative selection analysis
method (fast unconstrained Bayesian approximation [FUBAR]),
spike codon 509 is suggested to be under positive selection.
Population size. An estimation of the relative change in the
population size of MERS-CoV over time was made from the
GaussianMarkov random field (GMRF) Bayesian Skyride coales-
cent model (18), employed to infer the time-resolved phylogeny.
The Bayesian skyline plot (BSP) (Fig. 3) shows that after the first
documented MERS case in June 2012, the relative MERS-CoV
population size (i.e., the relative number of infections) increased
gradually, reaching a plateau at around April 2013. Since then, the
effective viral population size has decreased, reflecting the appar-
ent disappearance of multiple lineages (Riyadh_3, Buraidah_1,
and Al-Hasa) (Fig. 4A). Plotting genomes by clade and sample
time (Fig. 4A) shows that the viral clades appear limited in time,
although we note a long time interval between the beginning and
end of the Riyadh_3 cluster, suggesting the existence of unde-
tected cases. Under the assumption of limited missing cases, the
average time of existence (last observed date to first observed date)
(Fig. 4A, see the legend) is 98 days for the four clades, although the
last variant, Hafr-Al-Batin_1, was still in circulation at the end of
the observation period. All 9 of the recently identified viruses from
Riyadh are from the Hafr-Al-Batin_1 clade, and no further
Riyadh_3 variants have appeared in Riyadh.
Geography. The variations of MERS-CoV genome sequences
combined with sample collection dates and locations can help
identify the source of new MERS-CoV infections. Four MERS-
CoV monophyletic lineages containing 4 or more cases and per-
sisting for 2 months or more have been detected (Al-Hasa, Ri-
yadh_3, Buraidah_1, and Hafr-Al-Batin_1), and there are 6
sporadic viruses from Bisha, Riyadh, Makkah, and Al Zarqa, Jor-
dan (Fig. 1 and 4B). The geographical locations of all available
MERS-CoVgenomic sequences, labeled by clade, and the sporadic
viruses (clade size,4) are plotted in Fig. 4B. TheAl-Hasa variants
(Fig. 4B, gray circles) were not detected in any other part of Saudi
Arabia, and the Al-Hasa region has remained free of other virus
variants, indicating that the Al-Hasa virus source was constrained
to the Al-Hasa region. The more recently emerged Hafr-Al-
Batin_1 variant (Fig. 4B, green circles), is now found in three KSA
locations (Riyadh, Hafr-Al-Batin, andMadinah), as well as in Qa-
tar. Riyadh_3 viruses (Fig. 4B, orange circles) are geographically
dispersed and were found in Riyadh, Wadi Ad-Dawasir, and Ta’if
in Saudi Arabia, as well as Qatar/London (15) and Abu Dhabi/
Munich (16). The Buraidah_1 clade (Fig. 4B, blue circles) has
appeared in Buraidah, Ta’if, Musayt (in the southern province of
Asir), and in a patient from Dubai, United Arab Emirates, in Va-
lenciennes, France (19). The geographical dispersion of MERS-
CoV lineages suggests amobile infection source, either as human-
FIG 3 Bayesian skyline plot (BSP) showing the changes in effective population size of MERS-CoV across time. The dashed black line indicates the median
population size estimated from the BMCMC used in the inference of the time-resolved phylogeny (see Fig. 2 and Materials and Methods). The gray shading
indicates the 95% highest posterior density of the estimated population size.
Cotten et al.
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to-human or nonhuman-to-human infections or via transported
animal product.
Protein changes in MERS-CoV. The coding regions of the vi-
ral genome are evolving at an average rate of 1.12 103 substi-
tutions per site per year. Substitutions can be nonuniformly dis-
tributed, with coding regions constrained by protein function and
regions exposed to host innate or adaptive immune responses
showing greater levels of substitution. It is important to monitor
MERS-CoV amino acid substitutions that could signal adaptation
to human transmission, especially in proteins at the virus-host
A
B
FIG 4 Distribution ofMERS-CoVclades in time and space. (A)All availableMERS-CoVgenomeswere stratified by phylogenetic clade (see Fig. 1) andplotted by virus
sample date. The length of each clade was determined as the difference in days between the first and last observed sample of that virus and yielded the following values:
Al-Hasa (21 April 2013 to 22 June 2013; 62 days), Riyadh_3 (5 February 2013 to 2 July 2013; 147 days), Buraidah_1 viruses (3May 2013 to 5August 2013; 84 days), and
Hafr-Al-Batin_1 (4 June 2013 to 01October 2013; 119 days). (B) All availableMERS-CoV genomes were stratified by phylogenetic clade (see Fig. 1) and plotted by the
case location. Cities are indicated by small black circles, and sequenced viruses by larger circles colored according to phylogenetic clade.
Spread, Circulation, and Evolution of MERS-CoV
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interface. Changes in all MERS-CoV spike proteins are shown in
Fig. 5. Positive selection analysis using the MEME method re-
vealed that spike codon 1020 is under episodic selection, and using
the FUBAR method, codon 509 is suggested to be under modest
positive selection (see Materials and Methods). The codon 1020
substitution is in heptad repeat 1 (HR1) of the spike protein (Fig.
5; see also Fig. S1 in the supplementalmaterial, right panel), which
may influence the membrane fusion activity of the spike protein
(20). MERS-CoV genomes in the Al-Hasa and Hafr-Al-Batin_1
clades encode an arginine at this position, while the Riyadh_3
clade genome encodes a histidine. Nine genomes show amino acid
substitutions in the receptor-binding domain (RBD) of the spike
protein, including a recent genome, Riyadh_9, which has two
amino substitutions in the RBD (Fig. 5), and the two recent Qatar
genomes. Using a reported crystal structure of the human coro-
navirus ErasmusMedical Center/2012 (EMC/2012) RBD in com-
plex with the human receptor dipeptidyl peptidase 4 (DDP4) (21)
complex (Protein Data Bank [PDB] ID 4L72), nonsynonymous
mutations are observed in buried spike protein residues 482, 506,
and 534; all are conservative changes in terms of their amino acid
properties. A change of aspartic acid to glycine at codon 509 was
observed in the Riyadh_1 and Bisha_1 genomes, and this position
was found to be under modest positive selection. This residue is
not part of, but is immediately adjacent to, the spike-DPP4 bind-
ing interface (Fig. S1, left). However, none of the changes in the
RBD have been observed in multiple genomes, suggesting limited
transmission. Five amino acid substitutions persist in multiple
viruses (D158Y, Q1020R or Q1020H, T1202I, Q1208H, and
S460F) (Fig. 5), suggesting a neutral or positive consequence of
the variant for the virus. These include a Hafr-Al-Batin clade vari-
ant with both D158Y and Q1020R. These combined changes first
appeared inRiyadh_8 andHafr-Al-Batin_1 and are also present in
the later viruses Hafr-Al-Batin_2, 5, and 6, Riyadh_10, 11, 12, and
17, and Madinah_3. The S460F change in two recent Qatar ge-
nomes is close to the spike-DPP4 binding interface. None of these
changes reach significancewhen examined by all positive selection
algorithms.
DISCUSSION
The study reported here significantly extends our previous report
on 21 MERS-CoV genomes and the observation of three geneti-
cally distinct lineages of MERS-CoV circulating in Riyadh. We
FIG 5 Substitutions in MERS-CoV spike proteins. All available KSA MERS-CoV spike ORFs were translated, the proteins aligned, and amino acid differences
from the reconstructed ancestral clade Bprotein determined; changes observed inmore than one genome aremarked by vertical colored bars, with the new amino
acid residue coded as shown at the bottom. Gray bars indicate a gap in sequence coverage. Functional domains of the spike (S) protein are marked and include
the N-terminal domain, the receptor binding domain, the fusion domain (Fusion), heptad repeats 1 and 2 (HR1 and HR2) (20, 42), the transmembrane (TM)
domain, and the cytoplasmic (Endo) domain (43).
Cotten et al.
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concluded previously that it was unlikely that the Riyadh infec-
tions were the result of a single continuous human-to-human
transmission chain (17) and suggested that transmission within
Saudi Arabia was consistent with either movement of an animal
reservoir or animal products or movement of infected humans.
We now present additional data from 32 new MERS-CoV ge-
nomes which show that 4 phylogenetic clades of viruses have been
observed and 3 of these clades were no longer detected in cases at
the end of the current observation period. This pattern of clade
disappearancemay be due to the increasedMERS surveillance and
patient isolation that was implemented during the course of the
outbreak (14), combined with an R0 of less than 1 (11, 12), but it
could also reflect undiagnosed asymptomatic spread, and we note
the extended pattern of the Riyadh_3 cluster.
Adaptation of a zoonotic virus to a new host often requires
sustained replication of the virus in the new host for the selection
of amino acid changes that favor transmission. We find only lim-
ited evidence of adaptation to human transmission in the form of
positively selected amino acids in MERS-CoV lineages. However,
none of the MERS-CoV clades have been observed to persist be-
yond 2 to 3months, and thus, sustained human transmissionmay
not have occurred yet with MERS-CoV, although with the most
recent MERS-CoV Hafr-Al-Batin_1 variant, mortality has been
observed in two young healthy patients. It is essential that careful
monitoring of virus lineages and genome changes in the epidemic
is maintained and that the functional consequences of these sub-
stitutions in the spike and other viral proteins should be exam-
ined.
The spike amino acid changes to either arginine in the Hafr-
Al-Batin clade or histidine in the Riyadh_3 clade codon 1020 are
not predicted to change the alpha helical structure of this region
(Fig. S1, right); however, the histidine provides an endosomal
protonated residue and the arginine provides a potential endo-
somal protease cleavage site; either of these changesmight alter the
fusion function of this motif. The combination of HR1 with hep-
tad repeat 2 (HR2) and the fusion domain are essential compo-
nents of the fusion mechanism of the coronavirus spike protein
and allow passage of the virus across the endosomal membrane
(20). Changes in HR1 are associated with host range expansion of
murine hepatitis virus (22). The external orientation of the spike
protein may expose it to immune selection, and such changes are
important information when designing reagents for serological
testing. Changes in the coronavirus spike have been reported to
accompany coronavirus host switches (22) and the SARS corona-
virus adaptation to humans (23–25), and such changes should be
monitored for their effects on the receptor binding and transmis-
sion properties of the virus. In particular, spike changes of D158Y,
D509G, Q1020R Q1020H, T1202I, and Q1208H should be tested
for altered biological properties.
The MERS-CoV-encoded enzymes are obvious targets for an-
tiviral drugs, and screening efforts should use viral enzymes rep-
resentative of the currently circulating forms of the virus. The
major 3C protease, required formultiple cleavages of the replicase
polyproteins, shows a high level of conservation, with only three
nonsynonymous changes observed across all knownMERS-CoV.
The viral papain-like protease (PLP) is required for cleavage of the
open reading frame 1A (ORF1a) polyprotein and may antagonize
host immune signaling (26, 27). The Al-Hasa lineage shows a sus-
tained A160S substitution in PLP, while the later viruses in the
Hafr-Al-Batin lineage also have an R911C substitution in PLP,
close to the catalytic CHD triad. In addition, position 90 shows
substitutions in Jordan_N3_2012 (K90G) and Wadi-Ad-
Dawasir_1, Taif_1_2013, and Taif_4_2013 (K90E), and the
changes may be relevant for enzyme activity. The viral ADP-
ribose-1-monophosphatase (ADRP) has two conserved domains
required for activity: VNAAN at positions 290 to 294 and GIF at
384 to 386.Wadi-Ad-Dawasir_1 virus shows a change toVNAVN,
and a number of sustained amino acid substitutions have oc-
curred in the amino half of ADRP.
Considerable effort has been made to determine an animal
source for MERS-CoV. To date, serological evidence for a cross-
reactive virus in camels has been reported (7, 8), and a small frag-
ment of MERS-CoV sequence has been identified in a bat from
Saudi Arabia (9). Recently, a camel in contact with a case in Saudi
Arabia tested positive forMERS-CoVby PCR (28); however,mul-
tiple attempts at deep sequencing failed to yield convincing
MERS-CoV sequences from the 2 camel nasal samples, despite the
availability of a complete genome obtained from the patient
(M. Cotten, S. J. Watson, P. Kellam, H. Q. Makhdoom,
Z. A.Memish, unpublished results).More recently, 5 fragments of
sequence were obtained from a camel cared for by aMERS patient
in Qatar (10); these fragments were phylogenetically related to
whole-genome sequences of MERS-CoV from two patients in
contact with the camel (Qatar_3_2013 and Qatar_4_2013)
(Fig. 1), providing support for MERS-CoV infection in camels
and suggesting camels as an animal reservoir for the virus. Zoo-
notic movements from an animal reservoir to humans have oc-
curred with the SARS coronavirus (6, 25, 29). It is unclear to what
extent “chatter” occurs between such an animal reservoir and hu-
mans before a purely human infection becomes sustained. The
strongest argument for a persistent animal reservoir may be that
the occurrence of MERS-CoV infections in multiple sites in Saudi
Arabia, as well as in Jordan, Qatar, and United Arab Emirates
(Dubai and Abu Dhabi), is unlikely to be sustained by the ob-
served limited human-to-human MERS-CoV transmission, and
thus, a more widespread population of MERS-CoV in animals
could exist. However, the pattern of MERS-CoV lineages we have
documented here is not consistent with a uniform gradient of
MERS-CoV evolution across the Arabian peninsula. Instead, it is
more consistent with the movement of infected livestock or ani-
mal products. This conclusion is suggested by the appearance of
the Hafr-Al-Batin_1 lineage in Riyadh, Hafr-al-Batin, Madinah,
and Qatar or the Riyadh_3 lineage in Riyadh, Wadi Ad-Dawasir,
Ta’if, Qatar, and United Arab Emirates. The appearance of phylo-
genetically related MERS-CoV in geographically distant locations
must be taken into account in efforts to identify the animal source
and transmission of the virus.
We have estimated the time of themost recent common ances-
tor (tMRCA) as March 2012, consistent with the initial case de-
tection. It should be noted that the tMRCA only estimates when
the currently circulating viruses were last in a single host; it does
not tell us what that host was. Although we only have viral se-
quences isolated fromhumanpatients, it is plausible that this virus
was in an as-yet-unidentified animal reservoir. The fact that we
only have viruses isolated from human cases (and one camel
linked to a human case) may simply represent a strong ascertain-
ment bias toward severe human disease.
In conclusion, the rapid identification and isolation of cases,
combined with an R0 of less than 1, may control the human-to-
human transmission as long as the virus transmission properties
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TABLE 1 Summary of all MERS-CoV genomic sequences used in this study
Genome
Sample collection
date
Genome
fractiona GenBank accession number or source
Jordan_N3_2012 15 April 2012 1 KC776174
Bisha_1_2012 19 June 2012 1 KF600620
England-Qatar_2012 19 September 2012 1 KC667074
Riyadh_1_2012 23 October 2012 1 KF600612
Riyadh_2_2012 30 October 2012 1 KF600652
Riyadh_3_2013 5 February 2013 1 KF600613
England2-HPA_2013 10 February 2013 1 http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/MERSCoV
/respPartialgeneticsequenceofnovelcoronavirus/
Riyadh_4_2013 1 March 2013 1 KJ156952
Munich_AbuDhabi_2013 22 March 2013 1 KF192507
Al_Hasa_2_2013 21 April 2013 1 KF186566
Al_Hasa_3_2013 22 Apr 2013 1 KF186565
Al-Hasa_24_2013 1 May 2013 0.41 KJ156867, KJ156919, KJ156875, KJ156885, KJ156870, KJ156892,
KJ156902
Al_Hasa_4_2013 1 May 2013 1 KF186564
Al-Hasa_7_2013 1 May 2013 0.93 KF600623, KF600655
Al-Hasa_8_2013 1 May 2013 0.74 KF600618, KF600626, KF600635, KF600638
Al-Hasa_9_2013 1 May 2013 0.46 KF600622, KF600639, KF600648, KF600649, KF600654
Al-Hasa_25_2013 2 May 2013 1 KJ156866
Al-Hasa_10_2013 2 May 2013 0.32 KF600614, KF600624, KF600629, KF600636, KF600641, KF600642,
KF600646, KF600653
Al-Hasa_11_2013 3 May 2013 0.9 KF600629, KF600636, KF600646
Al-Hasa_12_2013 7 May 2013 1 KF600627
Al-Hasa_13_2013 7 May 2013 0.37 KF600616, KF600637, KF600640, KF600650, KF600656
France_UAE_2013 7 May 2013 0.99 KF745068
Al-Hasa_14_2013 8 May 2013 0.75 KF600615, KF600643
Al_Hasa_1_2013 9 May 2013 1 KF186567
Al-Hasa_22_2013 9 May 2013 0.47 KF600617, KF600619, KF600621, KF600625, KF600631, KF600633
Al-Hasa_15_2013 11 May 2013 1 KF600645
Al-Hasa_16_2013 12 May 2013 1 KF600644
Al-Hasa_23_2013 13 May 2013 0.76 KJ156860, KJ156894, KJ156929, KJ156923, KJ156862
Buraidah_1_2013 13 May 2013 1 KF600630
Al-Hasa_17_2013 15 May 2013 1 KF600647
Al-Hasa_19_2013 23 May 2013 1 KF600632
Al-Hasa_18_2013 23 May 2013 1 KF600651
Al-Hasa_21_2013 30 May 2013 1 KF600634
Hafr-Al-Batin_1_2013 4 June 2013 1 KF600628
Taif_1_2013 12 June 2013 1 KJ156949
Wadi-Ad-Dawasir_1_2013 12 June 2013 1 KJ156881
Taif_2_2013 12 June 2013 0.94 KJ156896, KJ156876
Taif_3_2013 13 Jun 2013 0.62 KJ156938, KJ156897, KJ156922, KJ156868, KJ156921, KJ156915,
KJ156906
Taif_4_2013 13 June 2013 0.27 KJ156886, KJ156871
Al-Hasa_26_2013 18 June 2013 0.99 KJ156882, KJ156941, KJ156872
Al-Hasa_27_2013 19 June 2013 0.94 KJ156943, KJ156939
Al-Hasa_28_2013 22 June 2013 0.71 KJ156887, KJ156940, KJ156889, KJ156893, KJ156884, KJ156930,
KJ156928, KJ156909
Riyadh_5_2013 2 July 2013 1 KJ156944
Riyadh_6_2013 2 July 2013 0.73 KJ156879, KJ156947, KJ156890, KJ156908, KJ156927
Asir_1_2013 2 July 2013 0.44 KJ156948, KJ156925, KJ156903, KJ156883
Riyadh_7_2013 15 July 2013 0.97 KJ156937, KJ156905
Riyadh_9_2013 17 July 2013 1 KJ156869
Riyadh_8_2013 17 July 2013 0.99 KJ156880, KJ156942
Hafr-Al-Batin_2_2013 5 August 2013 1 KJ156910
Riyadh_10_2013 5 August 2013 0.95 KJ156891, KJ156936, KJ156907
Asir_2_2013 5 August 2013 0.65 KJ156863, KJ156899, KJ156912, KJ156900, KJ156898, KJ156945,
KJ156932
Riyadh_11_2013 6 August 2013 0.94 KJ156946, KJ156911
Riyadh_12_2013 8 August 2013 0.95 KJ156926, KJ156901
Riyadh_13_2013 13 August 2013 0.97 KJ156888, KJ156873
Riyadh_14_2013 15 August 2013 1 KJ156934
Riyadh_15_2013 19 August 2013 0.49 KJ156914, KJ156877, KJ156878, KJ156859, KJ156933, KJ156953
Hafr-Al-Batin_5_2013 25 August 2013 0.63 KJ156951, KJ156924, KJ156954, KJ156913
(Continued on following page)
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remain the same. Full control of the MERS epidemic requires
identification of the source of infections to prevent the initiation
of the observed human-to-human transmission chains.
MATERIALS AND METHODS
Sequence generation.Nucleic acid extracts from PCR-confirmedMERS-
CoV-infected patient samples were processed for reverse transcription
and PCR amplification as previously described (15). Briefly, nucleic acids
were extracted from respiratory tract samples (Table 1) using automated
extraction. The MERS-CoV RNA genome was converted to DNA and
amplified byPCR in 15 overlapping amplicons. All amplicons for a sample
were pooled and processed into Illumina libraries, and sequencing was
performed with an Illumina MiSeq instrument to generate 2 million to 5
million 150-nucleotide paired-end reads per sample. The readsets were
processed to remove primer and adapter sequences by using QUASR (30)
and assembled into whole genomes using de novo assembly with SPAdes
(31). The assembly fidelity was verified bymonitoring intact open reading
frames and through comparison with the genome prepared with
reference-based assembly using SMALT (version 0.5.0) (32), with differ-
ences resolved by examining the raw read data.
Phylogeneticmethods.The 32 new genomes were aligned with the 33
published MERS-CoV genomes using MUSCLE (33) implemented in
MEGA5 (34). Bayesian inference of the phylogeny was performed with
MrBayes version 3.2.1 (35) using a general-time reversible (GTR) substi-
tution model with a 4-category discrete approximation of a gamma dis-
tribution (GTR	4) to represent among-site heterogeneity. For infer-
ence of the time-resolved phylogeny, a second, subalignment of 42
genomes was generated by removing epidemiologically linked sequences.
Sequences were considered linked if there was epidemiological evidence
for contact between the patients that was also supported by the viral ge-
netic data. If the observed number of mutations between the viral ge-
nomes fell below the 95%upper confidence interval of the Poisson cumu-
lative distribution function, whose expected value is calculated from the
evolutionary rate of the virus, the length of the genome, and the length of
time between the samples, then only the index genome was retained. The
main coding regions of the genome (encoding ORF1ab, S, E, M, and N)
were concatenated, and a codon-partitioning model of evolution applied
to the data set. Time-resolved phylogeny was inferred under a codon-
partitioned HKY	4 substitution model (Hasegawa, Kishino, and Yano
substitution model with a 4-category discrete approximation of a gamma
distribution), with an uncorrelated lognormal molecular clock and a
GMRF Bayesian Skyride coalescent model, using a Bayesian Markov-
chain Monte Carlo (BMCMC) approach implemented in BEAST version
1.8.0 (36). Ancestral geographical states were coestimated using the
Bayesian stochastic search variable selection (37). Models employing re-
versible or nonreversible transition rate matrices were assessed by com-
paring the marginal likelihood estimator of the BMCMC chains, pro-
duced through the path-sampling approach implemented in BEAST (38).
The Bayesian skyline plot, estimating the change in effective population
size through time, was generated from the BEAST BMCMC output files
using Tracer version 1.5. Hypothetical ancestral sequences were deter-
mined using a likelihood-based ancestral reconstruction method imple-
mented in HYPHY version 2.1.2 (39). Nonsynonymous substitutions
were determined using custom Python scripts. Codon positions under
episodic selection (40) were determined using the mixed effects model of
evolution (MEME) (40) or fast unconstrained Bayesian approximation
(FUBAR) (41) implemented in HYPHY.
Nucleotide sequence accession numbers. GenBank accession num-
bers for the new and previously published genomes are listed in Table 1.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org
/lookup/suppl/doi:10.1128/mBio.01062-13/-/DCSupplemental.
Figure S1, TIF file, 4.2 MB.
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